Abstract 2270
Background
Despite a population of over 180 million and over 115,950 new cases of cancer diagnosed every year, Nigeria has no dedicated medical oncologists (MO). Most oncology care is delivered through surgical (SO) and radiation oncologists (RO) who number less than 50 in the entire country. With the limited number of oncology professionals, cancer patients experience poor outcomes, with a less than 10% of 5-year cancer survival rate.
Methods
The participants were nominated by their institutions to attend the medical oncology training. Through the support of FSP and U.S. Embassy in Nigeria, MGM and TOC delivered 10-days of lectures based on ASCO, ESMO and NCCN guidelines in Abuja, Nigeria. Participants represented 15 Nigerian states, including 5 of the 6 ethnic and geographic regions. Mean correct scores of participants that completed both the pre- and post-course 25 question tests (composed by 2 of the authors TOC and MGM) were compared using GraphPad Prism 7.0a by Paired t-tests.
Results
Forty-four oncologists were identified of which 11 (25%) were females. Twenty-five (57%) completed both the pre- and post-tests and fully participated in the 10-day lecture series. 12 participates that completed the training were residents and 12 were attending physicians. One doctor did not identify as a resident or attending. Of the 25 that completed both tests, percentage of correct answers increased from 45% to 59% (2-sided p-value <0.0001). Benefits were seen both with attending doctors 45% to 59% (p = 0.0046) and resident doctors 45% to 59% (0.0007).
Conclusions
MO education coordinated by FSP and PPB improved MO knowledge in Nigeria regardless of participant background. Similar models may be employed across Sub-Saharan Africa. Reasons for lost participation need to be defined.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Project PinkBlue.
Funding
United States of America Department of State.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3469 - Ancillary evaluation of systemic immune antitumor response (SIAR) and tumor growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase 1 study Mel-Ipi-Rx.
Presenter: Celine Boutros
Session: Poster Display session 3
Resources:
Abstract
3252 - Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Presenter: Fernanda Costa Svedman
Session: Poster Display session 3
Resources:
Abstract
5545 - Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy
Presenter: Jessica Hassel
Session: Poster Display session 3
Resources:
Abstract
5213 - Genomic landscape of primary malignant melanoma of esophagus
Presenter: Jie Dai
Session: Poster Display session 3
Resources:
Abstract
2716 - A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
3550 - ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
Presenter: Marcus Butler
Session: Poster Display session 3
Resources:
Abstract
1645 - PRIME002 - Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy
Presenter: Andre Van Der Westhuizen
Session: Poster Display session 3
Resources:
Abstract
4440 - Pembrolizumab (pembro) Plus Lenvatinib (len) for First-Line Treatment of patients (pts) With Advanced Melanoma: Phase 3 LEAP-003 Study
Presenter: Alexander Eggermont
Session: Poster Display session 3
Resources:
Abstract
3454 - Proof of concept study with the histone deacetylase inhibitor vorinostat in patients with resistant BRAFV600 mutated advanced melanoma
Presenter: Sanne Huijberts
Session: Poster Display session 3
Resources:
Abstract
1832 - A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumor activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib).
Presenter: Lu Si
Session: Poster Display session 3
Resources:
Abstract